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ABSTRACT
The increased prevalence of diabetes mellitus has become a public health problem. Hyperglycaemia entails a rise in the 
morbidity and mortality of these patients. Although a direct relationship with periodontal disease has already been 
shown, little is known about the results of dental implants in diabetics.
The present paper reviews the bibliography linking the effect of diabetes on the osseointegration of implants and the 
healing of soft tissue. In experimental models of diabetes, a reduced level of bone-implant contact has been shown, 
and this can be reversed by means of treatment with insulin. Compared with the general population, a higher failure 
rate is seen in diabetic patients. Most of these occur during the first year of functional loading, seemingly pointing to 
the microvascular complications of this condition as a possible causal factor. These complications also compromise the 
healing of soft tissues. It is necessary to take certain special considerations into account for the placement of implants 
in diabetic patient. A good control of plasma glycaemia, together with other measures, has been shown to improve the 
percentages of implant survival in these patients.
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RESUMEN
El incremento en la prevalencia de la diabetes mellitus se ha convertido en un problema de salud pública. La hiperglu-
cemia conlleva un aumento en la morbilidad y mortalidad de estos pacientes. Aunque ya se ha demostrado una relación 
directa con la enfermedad periodontal, poco se conoce sobre el resultado del implante dental en el sujeto diabético.
En el presente trabajo se revisa la bibliografía que relaciona el efecto de la diabetes sobre la oseointegración de los im-
plantes y la cicatrización de los tejidos blandos. En modelos experimentales de diabetes se ha demostrado una reducción 
en los niveles de contacto hueso-implante, que puede ser revertida mediante tratamiento con insulina. En el paciente 
diabético, comparado con la población general, se observa un mayor índice de fracaso. La mayoría de ellos se producen 
durante el primer año de carga funcional, lo que parece señalar a las complicaciones microvasculares de la enfermedad 
como posible factor causal. Dichas complicaciones comprometen también la cicatrización de los tejidos blandos. Se hace 
necesario establecer unas consideraciones especiales para la colocación de implantes en el paciente diabético. El buen 
control de la glucemia plasmática, junto con otras medidas, ha demostrado mejorar los porcentajes de supervivencia 
de los implantes en estos pacientes.
Palabras clave: Diabetes Mellitus, hiperglucemia, oseointegración, implante.
Indexed in: 
-Index Medicus / MEDLINE  /  PubMed            
-EMBASE, Excerpta Medica
-SCOPUS
-Indice Médico Español                                                        
-IBECS
Med Oral Patol Oral Cir Bucal 2007;12:E38-43.                                                        �                                          Diabetes and implants                                                     Med Oral Patol Oral Cir Bucal 2007;12:E38-43.                                                        �                                        Diabetes and implants 
E39
© Medicina Oral S.L. Email: medicina@medicinaoral.com
INTRODUCTION
Diabetes Mellitus is a group of metabolic disorders charac-
terized by an increase in plasma glucose levels. This hyper-
glycaemia is the result of a defect in insulin secretion, insulin 
action, or both. It is one of the main causes of morbidity and 
mortality in modern society and has become an alarming 
public health problem. In the last decade, diabetes affected 
approximately 140 million individuals and it is expected to 
affect over 220 million by 2010 and more than 300 in 2025 
(1). The prevalence of diabetes mellitus in Spain is estimated 
at 6.2% for the 30 65 age group and 10% for 30  to 89-year-
olds, 90% of whom will be Type 2 diabetics (2).
Chronically high levels of  plasma glycaemia lead to the 
onset of chronic vascular complications of this condition, a 
frequent cause of morbidity and mortality in these patients 
(Figure 1). The treatment of  diabetes aims at achieving 
optimal metabolic control so as to avoid or delay these com-
plications (3). Over the last few years, special importance 
has been given to the relationship between diabetes and oral 
pathologies. Periodontal disease, frequently co-existing with 
diabetes, is considered to be a further complication of this 
disease. It affects both patients with type 1 and type 2 diabe-
tes mellitus, and it increases the risk of severe periodontitis 
by a factor of 3 to 4 times (4).
The impact of diabetes on dental implants has not yet been 
cleared up. The present article will review the implications 
of diabetes and glycaemic control for the prognosis and evo-
lution of dental implants, in order to establish, if  possible, 
a series of special considerations for these subjects.
EFFECT OF DIABETES ON BONE
1. Effect of hyperglycaemia
Chronic hyperglycaemia affects different tissue structures, 
produces an inflammatory effect and, in vitro, has been 
shown to be a stimulus for bone resorption. Bone loss in 
diabetes does not seem to depend so much on an increase in 
osteoclastogenesis as in the reduction in bone formation (5). 
Hyperglycaemia inhibits osteoblastic differentiation and al-
ters the response of the parathyroid hormone that regulates 
the metabolism of phosphorus and calcium (6). In addition, 
it produces a deleterious effect on the bone matrix and its 
components and also affects adherence, growth and accu-
mulation of extra-cellular matrix (7). Mineral homeostasis, 
production of osteoid and, in short, bone formation has 
been shown to be clearly diminished in various experimental 
models of diabetes (8) (Fig. 2).
2. Differences by type of diabetes
Type 1 diabetes mellitus is an auto-immune disease affecting 
the beta cells in the pancreas that produce insulin, thus 
making it necessary to use exogenous insulin to ensure 
survival and prevent or delay the chronic complications of 
this illness. Type 2 diabetes mellitus, on the other hand, is a 
multi-factorial disease resulting from environmental effects 
on genetically predisposed individuals and is related with 
obesity, age and a sedentary lifestyle. In these patients, there 
is a defect in the secretion of insulin together with a greater 
or lesser degree of insulinopenia. The treatment of type 2 
diabetics includes, in stages, measures relating to their diet 
and lifestyle, oral hypoglycaemic drugs either alone or in 
combination, and insulin. 
In both type 1 and type 2 diabetes, the therapeutic goal 
focuses on maintaining blood-glucose at normal or near-
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Fig. 1. Late-onset complications of diabetes.
1
Surgery for placement of 
the implant (osteotomy) 
Clot formation 
Bone resorption 





Alteration in protein synthesis 
Osteoclasts 




Bone metabolism alterations 
Changes in diabetic status 
Fig. 2. Possible alterations in bone healing in diabetic patients.
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to verify the mean glycaemia of a patient over the last 2 or 
3 months, thanks to the correlation between HbAc1 and 
mean levels of glycaemia shown in Table 1.
Type 1 diabetes produces a reduction in bone mineral density 
through mechanisms that have not yet been sufficiently clari-
fied; it has been attributed to both a lower formation of bone 
and also to a greater rate of bone loss (9). This alteration 
has not been demonstrated in patients with type 2 diabetes 
and, in some studies, it even seems that there is greater bone 
mineral density than in the control subjects (10,11). Expe-
rimental models of type 2 diabetes have shown a reduction 
in both bone formation and bone resorption, which might 
explain this apparently contradictory effect (5).
3. Effects of insulin on bone
Insulin directly stimulates the formation of  osteoblastic 
matrix. In experimental models of diabetes, the normogly-
caemia levels obtained by treatment with insulin brought 
about growth in bone matrix and formation of  osteoid 
similar to control subjects (12). While hyperglycaemia may 
reduce bone recovery by as much as 40% following circular 
osteotomies, treatment with insulin normalizes this recovery 
index, indicating that the deterioration of the bone is strictly 
related to poor control of diabetes (6).
EFFECTS OF DIABETES ON OSSEOINTEGRA-
TION OF IMPLANTS 
Although there are articles analyzing the success and failure 
rates for implants in diabetic patients, only experimental 
studies with animals have shown the effect of diabetes and 
insulin therapy on the osseointegration of implants.
1. Results of osseointegration of implants in experimental 
models of diabetes:
The analysis of the effect of diabetes on implants has revea-
led an alteration in bone remodelling processes and deficient 
mineralization, leading to less osseointegration. Some stu-
dies have shown that, although the amount of bone formed 
is similar when comparing diabetes-induced animals with 
controls, there is a reduction in the bone-implant contact 
in diabetics (13, 14). One study that analyzed the placement 
of implants in the femurs of diabetic rodents observed bone 
neoformation comparable to that of the control group in the 
region of the periosteum, whereas it was significantly lower 
in the endosteum and medullar canal, and bone bridges 
between the endosteum and the implant surface were only 
observed in a small number of cases (15).
The reduction in the levels of bone-implant contact confirms 
that diabetes inhibits osseointegration. This situation may 
be reversed by treating the hyperglycaemia and maintaining 
near-normal glucose levels (16).
In the light of the articles published, there is a higher proba-
bility that the implants will integrate in areas predominated 
by cortical bone. Nonetheless, further studies are necessary 
in humans to determine the biological factors affecting 
osseointegration in diabetic patients.
2. Effect of insulin on bone and osseointegration of implants 
in experimental models
Various researchers have confirmed that osteopenia associa-
ted with diabetes induced in animals can be reversed when 
treatment with insulin is applied (17).
When implants are placed in the tibia of diabetic rats, a 
reduction of 50% is observed in the bone formation area 
and on the contact surface between bone and implant. If  
insulin is used, the ultra-structural characteristics of the 
bone-implant interface become similar to those in the 
control group. These results suggest that metabolic control 
is essential for osseointegration to take place, as constant 
hyperglycaemia delays the healing of the bone around the 
implants (18). Although numerous studies have shown that 
insulin therapy allows regulation of bone formation around 
the implants and increases the amount of neoformed bone, 
it was not possible to equal the bone-implant contact when 
compared with non-diabetic groups (19). 
IMPLANTS IN PATIENTS WITH DIABETES 
MELLITUS 
Diabetes is currently classified as a relative contraindication 
for implant treatment. Compared with the general popula-
tion, a higher failure rate has been seen in diabetic patients 
with adequate metabolic control (20).
Reviewing the literature published in the last 10 years, the 
survival rate for implants in diabetic patients ranges between 
88.8% and 97.3% one year after placement, and 85.6% to 
94.6% in functional terms one year after the prosthesis was 
inserted. In a retrospective study with 215 implants placed 
in 40 diabetic patients, 31 failed implants were recorded, 24 
of which (11.2%) occurred in the first year of functional 
loading. This analysis shows a survival rate of 85.6% after 
6.5 years of functional use. The results obtained show a 
higher index of failures during the first year after placement 
of the prosthesis (21). Another study carried out with 227 
implants placed in 34 patients shows a success rate of 94.3% 
at the time of the second surgery, prior to the insertion of the 
prosthesis (22). In a meta-analysis with two implant systems 
placed in edentulous jaws, failure rates of 3.2% were obtai-
ned in the initial stages, whereas in the later stages (from 45 
months to 9 years), this figure increases to 5.4% (23).
HbAc1 (%)                             mg/dl                                     mmol/l 
6                                               135                                        7,5 
7                                               170                                        9,5 
8                                               205                                      11,5 
9                                               240                                      13,5 
10                                             275                                      15,5 
11                                             310                                      17,5 
12                                             345                                      19,5 
Table 1. Correlation between the level of  glycosylated haemoglobin 
(HbAc1) and mean levels of glycaemia (mg/dL, mmol/L ).
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A prospective study with 89 well-controlled type 2 diabetics 
in whose jaws a total of 178 implants had been placed reveals 
early failure rates of 2.2% (4 failures), increasing to 7.3% 
(9 further failures) one year after placement, indicating a 
survival rate of 92.7% within the first year of functional 
loading. The 5-year survival rate was 90% (24).
The fact that most failures occur after the second-phase 
surgery and during the first year of functional loading might 
indicate microvascular involvement is one of the factors 
implicated in implant failures in diabetic patients (25, 26). 
The percentages of failures in these studies are shown gra-
phically in Figure 3.
The microvascularization alteration associated with diabetes 
leads to a diminished immune response and a reduction in 
bone remodelling processes (24, 27). Most of the articles 
revised conclude that, despite the higher risk of failure in 
diabetic patients, maintaining adequate blood glucose levels 
along with other measures improves the implant survival 
rates in these patients (20, 25).
SPECIAL CONSIDERATIONS FOR THE PLA-
CEMENT OF IMPLANTS IN DIABETIC PA-
TIENTS
1. Healing and risk of post-operative infection:
The repercussions of diabetes on the healing of soft tis-
sue will depend on the degree of glycaemic control in the 
peri-operative period and the existence of chronic vascular 
complications.
Patients with poor metabolic control have their immune 
defences impaired: granulocytes have altered functionality 
with modifications in their movement towards the infec-
tion site and a deterioration in their microbicide activity, 
with greater predisposition to infection of the wound. In 
addition, the high concentration of blood-glucose and in 
body fluids encourages the growth of mycotic pathogens 
such as Candida.
The microangiopathy arising as a complication of diabetes 
may compromise the vascularization of the flap, thus de-
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Fig. 3. Graph of the percentage of failures in diabetic patients.
The left axis shows the time elapsed since the placement of the implants. The right-hand axis reflects the different phases from the placement 
of the implants until 1 year of functional loading after placement of the prosthesis.
The numbers in the columns indicate the percentages of failures in two distinct stages for each study. Early failures include up to one year 
of functional loading. Late failures have been monitored for up to 5 years.
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2. Peri-operative measures:
In view of  the studies revised, high levels of  glucose in 
plasma have a negative influence on healing and bone re-
modelling processes.
In order to ensure osseointegration of the implants, unders-
tood as the direct bond of the bone with the surface of the 
implant subjected to functional loading, and to avoid delays 
in the healing of gum tissue, it is necessary to maintain good 
glycaemic control before and after surgery. To measure the 
status of blood-glucose levels in the previous 6 8 weeks, we 
have to know the HbA1c values. A figure of less than 7% for 
HbA1c is considered a good level of glycaemic control (the 
normal value for healthy individuals is 3.5 5.5% depending 
on the laboratory).
Although there is some controversy over the use of  an-
tibiotics in healthy patients, these are recommendable in 
diabetic patients about to be subjected to implant surgery 
(22). The antibiotic of choice is amoxicillin (2 gr per os 1 
hour previously), as the pathogens most frequently causing 
post-operative complications following the placement of 
implants are Streptococci, Gram-positive anaerobes and 
Gram-negative anaerobes. Clindamycin may also be used 
(600 mg per os 1 hour previously), azithromycin or clari-
thromycin (500 mg per os 1 hour previously), and first-ge-
neration cephalosporins (cephalexin or cefadroxil: 2 gr per 
os 1 hour previously) only if  the patient has not had any 
anaphylactic allergic reaction to penicillin (29). In addition 
to antibiotic prophylaxis, the use of 0.12% chlorhexidine 
mouthwash has shown a clear benefit by reducing the fa-
ilure rates from 13.5% to 4.4% in type 2 diabetics, during a 
follow-up period of 36 months. This same study observed a 
reduction of 10.5% in the failure rate when antibiotics were 
administered pre-operatively (20). 
CONCLUSIONS
There is evidence that hyperglycaemia has a negative in-
fluence on bone formation and remodelling and reduces 
osseointegration of implants. Soft tissue is also affected by 
the microvascular complications deriving from hyperglycae-
mia, vascularization of the tissue is compromised, healing 
is delayed and wounds are more predisposed to infection. 
This entails an increase in the percentage of failures in the 
implant treatment of diabetic patients.
The bibliography reviewed recommends good glycaemic 
control in the peri-operative period in order to improve the 
survival rates for implants in diabetics. HbA1c figures of 
less than 7% indicate appropriate glycaemia levels in the 
preceding 6 8 weeks. Pre-operative antibiotic therapy and the 
use of 0.12% chlorhexidine mouthwash are recommended 
as both measures have been shown to reduce the percentage 
of failures.  
Although there is a higher risk of failure in diabetic patients, 
experimental studies have shown that the optimization of 
glycaemic control improves the degree of osseointegration 
in the implants. Nonetheless, it is necessary to extend the 
number of prospective studies in humans in order to clarify 
the true impact of diabetes on the prognosis for osseinte-
gration.
1.    Good glycaemic control: 
 HbA1c < 7%  
 Baseline and pre-prandial glycaemia (mg/dL): 80 - 110 
 Maximum post-prandial level of glycaemia (mg/dL): < 180 
2. Pre-operative antibiotic therapy   
3. 0.12% chlorhexidine mouthwash 
Table 2. Recommendations to reduce the risk of  implant failure in 
diabetic patients
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